Vortioxetine demonstrates a favourable cardiovascular profile in MDD patients with comorbidities, showing no association with QTc prolongation, arrhythmic risk, or significant blood pressure changes.
Does vortioxetine provide a safe cardiovascular profile and antidepressant efficacy in patients with MDD and chronic comorbidities?
Vortioxetine offers an optimal balance of efficacy and cardiovascular safety for patients with MDD and chronic comorbidities, making it a suitable choice for clinically vulnerable populations.
INTRODUCTION: Major depressive disorder (MDD) is a leading cause of disability and is frequently associated with chronic comorbidities, including cardiovascular, neurological, psychiatric, and systemic diseases. Selecting an appropriate antidepressant is crucial, as some agents may present cardiovascular risks such as QTc prolongation, blood pressure alterations, bleeding tendencies, and drug interactions. AREAS COVERED: This consensus evaluates the cardiovascular safety of vortioxetine in clinically vulnerable patients with MDD and multiple comorbidities, including cardiovascular disease, hypertension, diabetes, obesity, cerebrovascular disorders, and other neurological or psychiatric conditions. A targeted literature search was conducted in PubMed and Google Scholar for studies published between 2015 and 2024 using search terms related to "vortioxetine," "major depressive disorder," "cardiovascular comorbidity," "efficacy," and "safety." The analysis integrates available evidence on efficacy, tolerability, and cardiovascular outcomes. EXPERT OPINION: Vortioxetine demonstrates antidepressant efficacy and a favourable cardiovascular profile. It is not associated with QTc prolongation, arrhythmic risk, or significant effects on blood pressure, heart rate, or platelet aggregation. Its limited involvement in cytochrome P450 metabolism reduces the potential for drug interactions. Overall, vortioxetine offers an optimal balance of efficacy and safety for patients with MDD and chronic comorbidities. A multidisciplinary approach remains essential to improve treatment outcomes and quality of life.
Dell’Osso et al. (2025) conducted a review in Major depressive disorder with chronic comorbidities. Vortioxetine was evaluated on Cardiovascular safety and efficacy. Vortioxetine demonstrates a favourable cardiovascular profile in MDD patients with comorbidities, showing no association with QTc prolongation, arrhythmic risk, or significant blood pressure changes.